Scientific evidence classification · Phase 6A preserved + Phase 6B additions
PWWP Compounds
& Bioactivity
Explore experimentally studied preparations separately from deposited research ligands, buffers, ions and unresolved chemical evidence. Every role is source- and target-context specific.
Combined Phase 6A + Phase 6B denominators. These groups overlap; the 109 structurally source-tagged research ligands are unchanged. Deposited components and reagents are not automatically biochemical binders.
Evidence classification · exact source records
19 matching profiles
13 matching assay / association observations. Counts here are profiles, not unique assay events or deposited ligand instances; views overlap.
BI-9466
No source-curated measured assay in this context. Structural evidence is shown separately.
Measurements remain attached to the reported preparation.
compound 11 (Collie 2025)
No source-curated measured assay in this context. Structural evidence is shown separately.
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 12 (Collie 2025)
No source-curated measured assay in this context. Structural evidence is shown separately.
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 13 (Collie 2025)
No source-curated measured assay in this context. Structural evidence is shown separately.
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 5 (Collie 2025)
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 6 (Collie 2025)
Unresolved preparation · individual modeled components do not inherit its potency.
compound 7 (Collie 2025)
MS9715
Measurements remain attached to the reported preparation.
MS9715N
Unresolved preparation · individual modeled components do not inherit its potency.
UNC6934
2-[(~{E})-2-thiophen-2-ylethenyl]benzoic acid
No source-curated measured assay in this context. Structural evidence is shown separately.
3,5-dimethyl-4-(1-methyl-5-pyridin-4-yl-imidazol-4-yl)-1,2-oxazole
No source-curated measured assay in this context. Structural evidence is shown separately.
3,5-dimethyl-4-(4-pyridin-4-yl-1~{H}-pyrazol-3-yl)-1,2-oxazole
No source-curated measured assay in this context. Structural evidence is shown separately.
4-(3-methyl-5-phenyl-imidazol-4-yl)pyridine
No source-curated measured assay in this context. Structural evidence is shown separately.
4-[5-(7-fluoranylquinolin-4-yl)-1-methyl-imidazol-4-yl]-3,5-dimethyl-1,2-oxazole
No source-curated measured assay in this context. Structural evidence is shown separately.
5-methyl-2-piperidin-4-yl-6-pyridin-4-yl-pyridazin-3-one
No source-curated measured assay in this context. Structural evidence is shown separately.
5-methyl-6-phenyl-2-piperidin-4-yl-pyridazin-3-one
No source-curated measured assay in this context. Structural evidence is shown separately.
[3,5-dimethyl-4-(1-methyl-5-pyridin-4-yl-imidazol-4-yl)phenyl]methanamine
No source-curated measured assay in this context. Structural evidence is shown separately.